Simulations Plus (NASDAQ:SLP) Issues FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of $1.07 to $1.20 for the period, compared to the consensus EPS estimate of $0.63. The company issued revenue guidance of $90 million to $93 million, compared to the consensus revenue estimate of $91.76 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

Shares of NASDAQ SLP traded down $0.27 during mid-day trading on Wednesday, hitting $33.98. 399,370 shares of the stock traded hands, compared to its average volume of 126,490. The company has a market cap of $679.94 million, a price-to-earnings ratio of 71.35 and a beta of 0.69. The stock has a fifty day moving average price of $33.35 and a 200-day moving average price of $40.87. Simulations Plus has a 52 week low of $29.37 and a 52 week high of $51.22.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SLP shares. Craig Hallum reaffirmed a “buy” rating and issued a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. KeyCorp initiated coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price on the stock. JMP Securities began coverage on shares of Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Thursday, September 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $56.00.

Insider Activity at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $39.63, for a total transaction of $792,600.00. Following the transaction, the director now directly owns 3,521,592 shares of the company’s stock, valued at $139,560,690.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 60,750 shares of company stock worth $2,145,055. Corporate insiders own 20.90% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.